Silexion Therapeutics Ltd. (SLXN) Research

Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

Market snapshot

Symbol
SLXN
Price
$2.73
Day change
-5.86%
Market cap
$1.1M
P/E ratio
-0.07x
52-week range
2.31-223.6
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Azitra, Inc. (AZTR)
  • Enveric Biosciences, Inc. (ENVB)
  • Indaptus Therapeutics, Inc. (INDP)
  • Jasper Therapeutics, Inc. (JSPR)
  • Lipella Pharmaceuticals Inc. (LIPO)
  • Onconetix, Inc. (ONCO)
  • Protagenic Therapeutics, Inc. (PTIX)
  • Scinai Immunotherapeutics Ltd. (SCNI)

Recent insider activity

  • Shirvan Mitchell — A-Award (6000 shares) on 2026-06-04
  • Horenshtein Hadar Mirit — A-Award (7500 shares) on 2026-06-04
  • Hadar Ilan — A-Award (10000 shares) on 2026-06-04
  • Shirvan Mitchell — S-Sale (22818 shares) on 2026-03-26
  • Noy Shlomo — A-Award (9091 shares) on 2026-02-20

Open Silexion Therapeutics Ltd. (SLXN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.